Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Sponsor: Amgen
Terminated
This trial was terminated. No reason was provided.
A PHASE3 clinical study on Anemia and Cancer, this trial is terminated or withdrawn. The trial is conducted by Amgen and has accumulated 14 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE3
-
Sep 2025 — Jan 2026 [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2022 — Jul 2024 [monthly]
Terminated PHASE3
▶ Show 9 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE3
-
Aug 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Terminated PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Aug 2017 — Dec 2017 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
Apr 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jul 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .